Suppr超能文献

喹诺酮类药物的耐药机制。

Mechanisms of resistance to quinolones.

作者信息

Jacoby George A

机构信息

Lahey Clinic, Burlington, Massachusetts 01805, USA.

出版信息

Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S120-6. doi: 10.1086/428052.

Abstract

The increased use of fluoroquinolones has led to increasing resistance to these antimicrobials, with rates of resistance that vary by both organism and geographic region. Resistance to fluoroquinolones typically arises as a result of alterations in the target enzymes (DNA gyrase and topoisomerase IV) and of changes in drug entry and efflux. Mutations are selected first in the more susceptible target: DNA gyrase, in gram-negative bacteria, or topoisomerase IV, in gram-positive bacteria. Additional mutations in the next most susceptible target, as well as in genes controlling drug accumulation, augment resistance further, so that the most-resistant isolates have mutations in several genes. Resistance to quinolones can also be mediated by plasmids that produce the Qnr protein, which protects the quinolone targets from inhibition. Qnr plasmids have been found in the United States, Europe, and East Asia. Although Qnr by itself produces only low-level resistance, its presence facilitates the selection of higher-level resistance mutations, thus contributing to the alarming increase in resistance to quinolones.

摘要

氟喹诺酮类药物使用的增加导致对这些抗菌药物的耐药性不断上升,耐药率因微生物种类和地理区域而异。对氟喹诺酮类药物的耐药性通常是由于靶酶(DNA旋转酶和拓扑异构酶IV)的改变以及药物进入和流出的变化所致。突变首先在更敏感的靶标中被选择:在革兰氏阴性菌中是DNA旋转酶,在革兰氏阳性菌中是拓扑异构酶IV。下一个最敏感靶标以及控制药物积累的基因中的额外突变会进一步增强耐药性,因此耐药性最强的分离株在多个基因中都有突变。对喹诺酮类药物的耐药性也可由产生Qnr蛋白的质粒介导,该蛋白可保护喹诺酮类药物的靶标免受抑制。在美国、欧洲和东亚都发现了Qnr质粒。虽然Qnr本身仅产生低水平耐药性,但其存在有助于选择更高水平的耐药性突变,从而导致对喹诺酮类药物耐药性的惊人增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验